Wall Street Financial Group’s AnaptysBio ANAB Stock Holding History

Wall Street Financial Group’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75	Closed	-$4.16K	–	149
2026 Q1	$4.16K	Buy	+75	New	+$4.04K	﹤0.01%	516

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Wall Street Financial Group's ANAB Position: Q2 2026 in Review

Wall Street Financial Group sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 75 shares — an estimated $4.16K sold.

Wall Street Financial Group first reported a position in ANAB in Q1 2026 and held it in 1 quarter. The position peaked at $4.16K in Q1 2026. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Wall Street Financial Group reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
Wall Street Financial Group sold 75 AnaptysBio shares in Q2 2026, an estimated $4.16K.
Wall Street Financial Group first reported a position in AnaptysBio in Q1 2026 and held it in 1 quarter.
Wall Street Financial Group's AnaptysBio position peaked at $4.16K in Q1 2026.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Wall Street Financial Group's 13F filing for Q2 2026, filed 14 Jul 2026.